Advertisement

The Emergence of Drugs which Block Calcium Entry

  • Ronald D. Smith
  • Peter S. Wolf
  • John R. Regan
  • Stanley R. Jolly
Conference proceedings

Part of the Progress in Clinical Biochemistry and Medicine book series (PCBM, volume 6)

Table of contents

  1. Front Matter
    Pages I-VIII
  2. Ronald D. Smith, Peter S. Wolf, John R. Regan, Stanley R. Jolly
    Pages 1-1
  3. Ronald D. Smith, Peter S. Wolf, John R. Regan, Stanley R. Jolly
    Pages 2-20
  4. Ronald D. Smith, Peter S. Wolf, John R. Regan, Stanley R. Jolly
    Pages 21-43
  5. Ronald D. Smith, Peter S. Wolf, John R. Regan, Stanley R. Jolly
    Pages 44-72
  6. Ronald D. Smith, Peter S. Wolf, John R. Regan, Stanley R. Jolly
    Pages 73-102
  7. Ronald D. Smith, Peter S. Wolf, John R. Regan, Stanley R. Jolly
    Pages 103-111
  8. Ronald D. Smith, Peter S. Wolf, John R. Regan, Stanley R. Jolly
    Pages 112-114
  9. Ronald D. Smith, Peter S. Wolf, John R. Regan, Stanley R. Jolly
    Pages 114-114
  10. Ronald D. Smith, Peter S. Wolf, John R. Regan, Stanley R. Jolly
    Pages 115-152
  11. Back Matter
    Pages 153-156

About these proceedings

Introduction

Calcium Entry Blockers (CEBs) are a new class of drugs which have been pushing back the frontiers of science and medicine for almost two decades. This report reviews some of the wealth of chemical, biological and clinical data describing the discovery and development of these compounds. The scientific importance, therapeutic benefit and marketing potential of these compounds have caused an explosion of scientific literature describing their effects in many preclinical and clinical settings. The definitional characteristics of these compounds suggest a certain predictability of their biological profile but their therapeutic usefulness varies widely dependent upon their physical properties, net hemodynamic effects, duration of action and incidence of side effects. CEBs appear uniquely suited to the treatment of the underlying complexity of cardiovascular disease. The CEBs of the future may live up to the expectations of pathophysiologically based therapeutics and allow the heart and blood vessels to outlive the cells which they support. The development of CEBs is an evolving story of epic proportions and represents the cooperative efforts of individuals in all areas of science.

Keywords

angina pectoris arrhythmia asthma atherosclerosis calcium cardiovascular disease drug drug discovery drugs heart heart disease heart failure pharmacology research vascular disease

Authors and affiliations

  • Ronald D. Smith
    • 1
  • Peter S. Wolf
    • 2
  • John R. Regan
    • 3
  • Stanley R. Jolly
    • 4
  1. 1.Department of Pharmaceutical ResearchDu Pont Critical CareWaukeganUSA
  2. 2.Sterling Drug, Inc.New YorkUSA
  3. 3.Rorer Central ResearchFort WashingtonUSA
  4. 4.East Carolina University, School of MedicineGreenvilleUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-3-642-73228-7
  • Copyright Information Springer-Verlag Berlin Heidelberg 1988
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-642-73230-0
  • Online ISBN 978-3-642-73228-7
  • Series Print ISSN 0177-8757
  • Buy this book on publisher's site